Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD): HIV Outpaces HCV Decline, PT To $95 - Wells Fargo

July 26, 2018 6:35 AM
Wells Fargo analyst, Jim Birchenough, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) and raised his price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles